Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

…limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of… clinical trials, visit http://ift.tt/1np5kw2. About Merck For 125 years, Merck has been a global health care leader working to help the world be…

mercknewsroom.com

Total Shares: 0

from Data Alerts http://ift.tt/2b0LXW1
via IFTTT

One thought on “Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

  1. Have you ever considered publishing an e-book or guest authoring on other blogs? I have a blog based upon on the same topics you discuss and would really like to have you share some stories/information. I know my viewers would enjoy your work. If you’re even remotely interested, feel free to send me an e-mail.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

WordPress spam blocked by CleanTalk.